Immunotherapy for glioblastoma: the promise of combination strategies

M Bausart, V Préat, A Malfanti - Journal of Experimental & Clinical Cancer …, 2022 - Springer
Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The
current standard of care involves surgical resection (if possible) followed by concomitant …

Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment

F Hanif, K Muzaffar, K Perveen… - Asian Pacific journal …, 2017 - pmc.ncbi.nlm.nih.gov
Glioblastoma multiforme (GBM) is one of the most malignant types of central nervous system
tumors. Despite advances in treatment modalities it remains largely incurable. The objective …

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies

Z An, O Aksoy, T Zheng, QW Fan, WA Weiss - Oncogene, 2018 - nature.com
Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII
occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in …

Adult glioblastoma

BM Alexander, TF Cloughesy - Journal of Clinical Oncology, 2017 - ascopubs.org
Glioblastoma (GBM) is a rare tumor and one of the most challenging malignancies to treat in
all of oncology. Although advances have been made in the treatment of GBM, encouraging …